Valion Bio enters Initial Closing for $1.5M Series B Preferred shares
Valion Bio reached an Initial Closing for 1,500 Series B Preferred shares following an agreement with investor 3i, LP. The closing is contingent on CEO Michael Handley's resignation.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day